Literature DB >> 10769083

Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59.

I G Goodfellow1, R M Powell, T Ward, O B Spiller, J W Almond, D J Evans.   

Abstract

A number of echoviruses use decay accelerating factor (DAF) as a cellular receptor or attachment protein for cell infection. Binding of echovirus 7 to DAF at the cell surface, but not to soluble DAF in solution, triggers the formation of virus particles exhibiting an altered sedimentation coefficient ('A' particles) which are considered indicative of the particle uncoating process. We have previously demonstrated that antibodies to beta(2)-microglobulin block cell infection at a stage prior to 'A' particle formation and suggested that this reflects the involvement of beta(2)-microglobulin (or the associated MHC-I) in a virus-receptor complex that forms at the cell surface. We demonstrate here that antiserum to CD59 specifically blocks infection of rhabdomyosarcoma cells by a range of echoviruses, including viruses that bind DAF (e. g. echovirus 7) and those that use currently unidentified receptors other than DAF. The block occurs prior to 'A' particle formation and is cell-type specific. The potential role of CD59 as an active member, or passive participant, in the virus-receptor complex is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769083     DOI: 10.1099/0022-1317-81-5-1393

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Picornaviruses.

Authors:  Tobias J Tuthill; Elisabetta Groppelli; James M Hogle; David J Rowlands
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Fatty acid-depleted albumin induces the formation of echovirus A particles.

Authors:  T Ward; R M Powell; Y Chaudhry; J Meredith; J W Almond; W Kraus; B Nelsen-Salz; H J Eggers; D J Evans
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  The neonatal Fc receptor is a pan-echovirus receptor.

Authors:  Stefanie Morosky; Alexandra I Wells; Kathryn Lemon; Azia S Evans; Sandra Schamus; Christopher J Bakkenist; Carolyn B Coyne
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

Review 4.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein).

Authors:  J A Cummerson; B F Flanagan; D G Spiller; P M Johnson
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

6.  Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells.

Authors:  P Ylipaasto; K Klingel; A M Lindberg; T Otonkoski; R Kandolf; T Hovi; M Roivainen
Journal:  Diabetologia       Date:  2004-01-15       Impact factor: 10.122

7.  Interaction of decay-accelerating factor with coxsackievirus B3.

Authors:  Susan Hafenstein; Valorie D Bowman; Paul R Chipman; Carol M Bator Kelly; Feng Lin; M Edward Medof; Michael G Rossmann
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

Review 8.  Evolution of cell recognition by viruses: a source of biological novelty with medical implications.

Authors:  Eric Baranowski; Carmen M Ruiz-Jarabo; Nonia Pariente; Nuria Verdaguer; Esteban Domingo
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

Review 9.  Xenotransplantation: the next generation of engineered animals.

Authors:  Anthony J F d'Apice; Peter J Cowan
Journal:  Transpl Immunol       Date:  2008-10-28       Impact factor: 1.708

10.  A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts.

Authors:  Amanda D Stuart; Hannah E Eustace; Thomas A McKee; T D K Brown
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.